Genscript Biotech Corporation (G51) - Total Liabilities

Latest as of December 2025: €888.59 Million EUR ≈ $1.04 Billion USD

Based on the latest financial reports, Genscript Biotech Corporation (G51) has total liabilities worth €888.59 Million EUR (≈ $1.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore G51 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Genscript Biotech Corporation - Total Liabilities Trend (2016–2025)

This chart illustrates how Genscript Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. See Genscript Biotech Corporation free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Genscript Biotech Corporation Competitors by Total Liabilities

The table below lists competitors of Genscript Biotech Corporation ranked by their total liabilities.

Company	Country	Total Liabilities
Signet Jewelers Ltd NYSE:SIG	USA	$3.83 Billion
Breville Group Ltd AU:BRG	Australia	AU$749.94 Million
Assured Guaranty Ltd NYSE:AGO	USA	$7.07 Billion
Impinj Inc NASDAQ:PI	USA	$335.95 Million
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥3.18 Billion
China Railway Construction Heavy Industry Corp Ltd SHG:688425	China	CN¥8.48 Billion
MERCARI INC. UNSP.ADR/1/2 F:6TP0	Germany	€503.91 Billion
INVENTURUS KNOWLEDGE SO L NSE:IKS	India	Rs14.68 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Genscript Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genscript Biotech Corporation stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.50	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.22	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genscript Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genscript Biotech Corporation (2016–2025)

The table below shows the annual total liabilities of Genscript Biotech Corporation from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€888.59 Million ≈ $1.04 Billion	-6.95%
2024-12-31	€954.91 Million ≈ $1.12 Billion	-28.89%
2023-12-31	€1.34 Billion ≈ $1.57 Billion	+13.45%
2022-12-31	€1.18 Billion ≈ $1.38 Billion	+3.85%
2021-12-31	€1.14 Billion ≈ $1.33 Billion	+80.40%
2020-12-31	€631.82 Million ≈ $738.66 Million	+22.18%
2019-12-31	€517.11 Million ≈ $604.56 Million	+22.05%
2018-12-31	€423.68 Million ≈ $495.32 Million	+53.54%
2017-12-31	€275.94 Million ≈ $322.61 Million	+556.84%
2016-12-31	€42.01 Million ≈ $49.12 Million	--

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$5.01 Billion

€4.28 Billion EUR

Market Cap Rank

#4518 Global

#784 in Germany

Share Price

€1.96

Change (1 day)

+4.81%

52-Week Range

€1.14 - €2.04

All Time High

€4.62